We previously reported that intracerebroventricularly (i.c.v.) administered corticotropin-releasing factor (CRF) (0.5-3.0 nmol/animal) dose-dependently elevates plasma noradrenaline and adrenaline through brain phospholipase C-, diacylglycerol lipase-and prostanoids-mediated mechanisms in rats. Diacylglycerol produced by phospholipase C from phospholipids can be hydrolyzed by diacylglycerol lipase into 2-arachidonoylglycerol, which may be further hydrolyzed by monoacylglycerol lipase into arachidonic acid, a precursor of prostanoids. Recently, 2-arachidonoylglycerol has been recognized as a major brain endocannabinoid, which can modulate synaptic transmission through presynaptic cannabinoid CB 1 receptors. Released 2-arachidonoylglycerol is rapidly deactivated by uptake into cells and enzymatic hydrolysis. In the present study, therefore, we examined (1) the involvement of brain 2-arachidonoylglycerol, (2) the regulatory role of 2-arachidonoylglycerol as a brain endocannabinoid, and (3) the effect of exogenous cannabinoid receptor agonist, on the CRF-induced elevation of plasma noradrenaline and adrenaline using anesthetized rats. 
Introduction
The endogenous cannabinoids that have received the most experimental attention are the arachidonic acid-containing lipids known as anandamide and 2-arachidonylglycerol. 2-Arachidonoylglycerol has been recognized as a major brain endocannabinoid because it acts as a full agonist at cannabinoid CB receptors while anandamide acts as a partial agonist (Sugiura and Waku, 2000) and 2-arachidonoylglycerol is several 100-fold more abundant than anandamide in the brain Sugiura and Waku, 2000) . 2-Arachidonoylglycerol produced on demand from membrane phospholipid of postsynaptic neurons acts on presynaptic cannabinoid CB 1 receptors, thereby inhibiting the release of neurotransmitters Kreitzer and Regehr, 2001; Ohno-Shosaku et al., 2001; Freund et al., 2003) . The released 2-arachidonoylglycerol into the synaptic cleft is considered to be rapidly inactivated by uptake into neurons (Di Marzo, 2006; Centonze et al., 2007; Bisogno, 2008) . The 2-arachidonoylglycerol-induced retrograde signaling process seems to be involved in the widespread central effects including synaptic plasticity (Heifets and Castillo, 2009) , neuroprotection (Centonze et al., 2007) , epilepsy (Ludányi et al., 2008) , depression (Vinod and Hungund, 2006) , food intake (Di Marzo et al., 2009) , and also in the baroreflex-evoked central sympathetic modulation (Brozoski et al., 2005) .
2-Arachidonoylglycerol is generated from diacylglycerol, which is produced by hydrolysis of arachidonic acid-enriched membrane phospholipids through phospholipase C Di Marzo, 2006; Tang et al., 2006; Bisogno, 2008) . Diacylglycerol containing arachidonic acid in position 2 is hydrolyzed to 2-arachidonoylglycerol by sn-1 selective diacylglycerol lipase Bisogno et al., 2003; Di Marzo, 2006; Tang et al., 2006; Bisogno, 2008) . Actually, overexpression of the lipase in mouse neuroblastoma increases basal 2-arachidonoylglycerol levels (Jung et al., 2007) . 2-Arachidonoylglycerol can be further hydrolyzed by monoacylglycerol lipase to generate arachidonic acid and glycerol (Dinh et al., 2002; Di Marzo, 2006; Tang et al., 2006; Bisogno, 2008) . Recently, we reported the involvement of brain arachidonic acid generated by brain phospholipase C-, diacylglycerol lipase-and monoacylglycerol lipase-mediated mechanisms in centrally administered arginine-vasopressin-induced elevation of plasma noradrenaline and adrenaline in rats (Shimizu et al., 2004; Shimizu and Yokotani, 2008) . Brain arachidonic acid has already been shown to be involved as a precursor of prostanoids in this peptide-induced elevation of plasma catecholamines (Yokotani et al., 1995 (Yokotani et al., , 2000 Murakami et al., 2002; Okada et al., 2003a) . Furthermore, it is interesting to note that 2-arachidonoylglycerol, a precursor of arachidonic acid, plays a modulating role as an endocannabinoid to inhibit the arginine-vasopressin-induced response (Shimizu and Yokotani, 2008) .
Previously, we also reported that brain phospholipase C, diacylglycerol lipase and prostanoids are involved in the centrally administered corticotropin-releasing factor (CRF)-induced elevation of plasma noradrenaline and adrenaline in rats (Yokotani et al., 2001; Okada et al., 2003b) . Therefore we propose, on the basis of recent studies in our laboratory, to examine (1) the involvement of brain 2-arachidonoylglycerol in the CRF-induced response. Furthermore, we examined (2) the regulatory role of 2-arachidonoylglycerol as a brain endocannabinoid, and (3) the effect 6 of centrally administered cannabinoid receptor agonist on the CRF-induced response, in anesthetized rats. 7
Materials and methods

Experimental procedures
All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by Kochi University, which are in accordance with the "Guidelines for proper conduct of animal experiments" from the Science Council of Japan. Male Wistar rats weighing about 350 g were maintained in an air-conditioned room at 22-24°C under a constant day-night rhythm for more than 2 weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. In the morning (09:00~10:00), the femoral vein was cannulated for infusion of saline (1.2 ml/h) and the femoral artery was cannulated for collecting blood samples, under urethane anesthesia (1.2 g/kg, i.p.). After these procedures, the animal was placed in a stereotaxic apparatus until the end of each experiment, as shown in our previous papers (Yokotani et al., 1995; Shimizu et al., 2004) . The skull was drilled for intracerebroventricular administration of test substances using a stainless-steel cannula (0.3 mm outer diameter). The stereotaxic coordinates of the tip of the cannula were as follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from the midline; V, below the surface of the brain), according to the rat brain atlas (Paxinos and Watson, 2005) . Three hours were allowed to elapse before the application of reagents.
MAFP (a monoacylglycerol lipase inhibitor), AM 251 (a cannabinoid CB 1 receptor antagonist), AM 404 (an uptake-inhibitor of endocannabinoid) and ACEA (a cannabinoid CB 1 receptor agonist) dissolved in 3 µl of 100% N,N-dimethylformamide 8 (DMF)/animal were intracerebroventricularly (i.c.v.) administered using the cannula connected to a 10-µl Hamilton syringe, which was retained for 15 min to avoid the leakage of these reagents and then removed from the ventricle. CRF dissolved in sterile saline in a volume of 10 µl/animal was then slowly administered into the ventricle, 30 min after application of MAFP, AM 251 and ACEA and 60 min after application of AM 404, due to their slightly elevating effects on the basal plasma levels of catecholamines, using the same cannula connected to a 25-µl Hamilton syringe. The cannula was retained until the end of the experiment.
Measurement of plasma catecholamines
Blood samples (250 µl) were collected through an arterial catheter and were preserved on ice during experiments. Plasma was prepared immediately after the final sampling. Catecholamines in the plasma were extracted by the method of Anton and Sayre (1962) with a slight modification and were assayed electrochemically with high performance liquid chromatography (HPLC) (Shimizu et al., 2004) . Briefly, after centrifugation (1,500 g for 10 min, at 4°C), the plasma (100 µl) was transferred to a centrifuge tube containing 30 mg of activated alumina, 2 ml of twice deionized water, 1 ml of 1.5 M Tris buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the alumina was washed three times with 4 ml of ice-cold twice deionized water. Then, catecholamines adsorbed onto the alumina were eluted with 300 µl of 4% acetic acid containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical 9 detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC.
Analytical conditions were as follows: detector, +450 mV potential against an Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 -Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l sodium 1-octanesulfonate and 15% methanol at a flow rate of 0.18 ml/min; injection volume, 40 µl. The amount of catecholamines in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of variation for the intra-and inter-assay were 3.0 and 3.7%, respectively, and 0.5 pg of noradrenaline and adrenaline was accurately determined.
Treatment of data and statistics
Increments of plasma catecholamines above the basal level at each time are expressed as pg/ml. The area under the curve (AUC) is also expressed as pg/2 h. The number of animals in each group is shown in all figures. All values are expressed as the mean±S.E.M. Statistical differences are determined using repeated-measure (treatment × time) or one-way analysis of variance (ANOVA), followed by post-hoc analysis with the Bonferroni method. P values less than 0.05 were taken to indicate statistical significance.
Compounds
Results
Effect of MAFP on the centrally administered CRF (1.5 nmol/animal)-induced elevation of plasma catecholamines
Repeated-measure ANOVA showed for plasma levels of catecholamines (noradrenaline and adrenaline) significant effects of treatment [noradrenaline, F(4,18)=26.42, P<0.05; adrenaline, F(4,18) (Fig. 1A) . One-way ANOVA also revealed significant effects of treatment on plasma catecholamines [noradrenaline, F(4,17)=26.39, P<0.05; adrenaline, F(4,18)=74.24, P<0.05] (Fig. 1B) .
Treatments with vehicle-1 (3 µl DMF/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 1, A and B) . Pretreatment with MAFP (an inhibitor of monoacylglycerol lipase) [1.4 µmol (500 µg)/animal, i.c.v.] had a slight, but significant inhibitory effect on the basal plasma noradrenaline level, but had no significant effect on the basal plasma adrenaline level (Fig. 1, A and B ).
Since we previously reported that CRF (0.5, 1.5 and 3.0 nmol/animal, i.c.v.) dose-dependently elevated plasma levels of noradrenaline and adrenaline (Yokotani et al., 2001 ), we used a sub-maximum dose of 1.5 nmol/animal in the present study.
Administration of CRF (1.5 nmol/animal, i.c.v.) gradually elevated the plasma levels of noradrenaline and adrenaline and the responses reached a maximum 90 min after the 12 administration of this peptide (Fig. 1A) . The CRF-induced elevation of both catecholamines was reduced by MAFP in a dose-dependent manner [0.7 and 1.4 µmol (250 and 500 µg)/animal, i.c.v.] (Fig. 1, A and B) .
Effect of AM 251 on the centrally administered CRF (0.5 nmol/animal)-induced elevation of plasma catecholamines
Repeated-measure ANOVA showed for plasma levels of catecholamines (noradrenaline and adrenaline) significant effects of treatment [noradrenaline, F(4,20)=21.85, P<0.05; adrenaline, F(4,20) (Fig. 2A) . One-way ANOVA also revealed significant effects of treatment on plasma catecholamines [noradrenaline, F(4,20)=21.09, P<0.05; adrenaline, F(4,19)=27.78, P<0.05] (Fig. 2B ).
Pretreatment with AM 251 (a selective antagonist of cannabinoid CB 1 receptors)
[180 nmol (100 µg)/animal, i.c.v.] had no significant effect on the basal plasma levels of both catecholamines (Fig. 2, A and B) .
In this experiment, we used a small dose of CRF (0.5 nmol/animal, i.c.v.) to clarify the potentiating effect of cannabinoid CB 1 receptor antagonist on plasma catecholamines induced by this peptide. Administration of CRF (0.5 nmol/animal, i.c.v.) slightly, but significantly elevated plasma levels of noradrenaline and adrenaline during 120 min after the administration of this peptide (Fig. 2A) . The CRF-induced 13 elevation of both catecholamines was potentiated by AM 251 in a dose-dependent manner [90 and 180 nmol (50 and 100 µg)/animal, i.c.v.] (Fig. 2, A and B (Fig. 3A) . One-way ANOVA also revealed significant effects of treatment on plasma catecholamines [noradrenaline, F(4,21)=25.86, P<0.05; adrenaline, F(4,21)=23.18, P<0.05] (Fig. 3B) .
Treatments with vehicle-1 (3 µl DMF/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 3, A and B) . Pretreatment with AM 404 (an uptake-inhibitor of endocannabinoid) [250 nmol (100 µg)/animal, i.c.v.] had no significant effect on the basal plasma levels of both catecholamines (Fig. 3, A and B) . (Fig. 3, A and B (Fig. 4B) .
Pretreatment with ACEA (a selective agonist of cannabinoid CB 1 receptors) [1.4 µmol (500 µg)/animal, i.c.v.] had no significant effect on the basal plasma levels of both catecholamines (Fig. 4, A (Fig. 4, A and B) . On the other hand, intravenous administration of ACEA (1.4 µmol/animal) had no effect on the CRF-induced response (data not shown).
Discussion
2-Arachidonoylglycerol generated by phospholipase C and sn-1 selective diacylglycerol lipase Bisogno et al., 2003; Di Marzo, 2006; Tang et al., 2006; Bisogno, 2008) can be hydrolyzed by monoacylglycerol lipase to arachidonic acid (Dinh et al., 2002; Di Marzo, 2006; Quistad et al., 2006; Tang et al., 2006; Blankman et al., 2007; Bisogno, 2008) . In addition, arachidonic acid can be also produced from diacylglycerol containing the fatty acid in position 2 by sn-2 selective diacylglycerol lipase (Bell et al., 1979) . Brain phospholipase C, diacylglycerol lipase and prostanoids, active metabolites of arachidonic acid, have been shown to be involved in the centrally administered CRF-induced elevation of plasma noradrenaline and adrenaline (Yokotani et al., 2001; Okada et al., 2003b) . Therefore, we examined whether 2-arachidonoylglycerol is involved as a precursor of arachidonic acid in the CRF-induced response using MAFP. This reagent is currently recognized as a very potent inhibitor of 2-arachidonoylglycerol hydrolyzing enzymatic activity with an IC 50 value of 2-3 nM (Goparaju et al., 1999; Saario et al., 2004) and actually accumulates endogenous 2-arachidonoylglycerol in rat brain sections (Palomäki et al., 2007) .
Previously we also reported that centrally administered MAFP also reduced the elevation of plasma catecholamines induced by centrally administered 2-arachidonoylglycerol (Shimizu and Yokotani, 2008) . In the present experiment, centrally administered MAFP effectively reduced the CRF-induced elevation of plasma catecholamines, suggesting the involvement of brain 2-arachidonoylglycerol generated by sn-1 selective diacylglycerol lipase in the CRF-induced activation of central sympatho-adrenomedullary outflow in rats.
Recently, 2-arachidonoylglycerol has been recognized as a major endogenous ligand for two cannabinoid receptors, CB 1 and CB 2 (Matsuda et al., 1990; Munro et al., 1993) . Cannabinoid CB 1 receptors are predominantly expressed in the central nervous system, whereas cannabinoid CB 2 receptors are present mainly in the immune system (Howlett et al., 2002; Mackie, 2008) . Brain 2-arachidonoylglycerol has been shown to inhibit neurotransmission through presynaptic cannabinoid CB 1 receptors (OhnoShosaku et al., 2001; Freund et al., 2003) and we recently reported that brain cannabinoid CB 1 receptors, but not cannabinoid CB 2 receptors, play an inhibitory role in the centrally administered arginine-vasopressin-induced elevation of plasma catecholamines (Shimizu and Yokotani, 2008) . Therefore we examined whether the endogenously generated 2-arachidonoylglycerol has an inhibitory role as an endocannabinoid in the centrally administered CRF-induced elevation of plasma catecholamines with regard to cannabinoid CB 1 receptors. In the present experiment, we used a selective cannabinoid CB 1 receptor antagonist AM 251 (Lan et al., 1999) , which actually reverses the orexigenic effect induced by 2-arachidonoylglycerol administered into pontine parabrachial nucleus in rats (DiPatrizio and Simansky, 2008) and the protective effect against brain ischemia caused by electroacupuncture-induced elevation of brain 2-arachidonoylglycerol content in rats (Wang et al., 2009 ). Centrally pretreated AM 251 effectively potentiated the elevation of plasma catecholamines induced by a small dose of CRF, suggesting a possibility that endogenously generated 2-arachidonoylglycerol has an inhibitory effect on the CRF-induced activation of central sympatho-adrenomedullary outflow through cannabinoid CB 1 receptors in rats.
The released 2-arachidonoylglycerol into the synaptic cleft in the brain seems to be rapidly uptaken into neurons and degraded for termination of the endocannabinoid signaling (Di Marzo, 2006; Centonze et al., 2007; Bisogno, 2008) . The uptake is considered to occur through a plasma membrane transporter that has not been isolated or cloned yet (Bisogno, 2008) . Several reagents, including AM 404, have been shown to inhibit the cellular uptake of 2-arachidonoylglycerol (Centonze et al., 2007) . AM 404 was originally reported as an inhibitor of anandamide transport (Beltramo et al., 1997) , and this reagent actually induces anandamide accumulation in the rat brain (Giuffrida et al., 2001 ) and increases an activity-dependent anandamide level in rat hypothalamic slices (Di et al., 2005) . Interestingly, AM 404 also elicits an activitydependent increase of 2-arachidonoylglycerol in rat hypothalamic slices (Di et al., 2005) and inhibits the uptake of 2-arachidonoylglycerol in C6 glioma cells (Bisogno et al., 2001) . In the present experiment, central pretreatment with AM 404 effectively reduced the centrally administered CRF-induced elevation of plasma catecholamines, suggesting a possibility that AM 404-induced synaptic accumulation of endogenously generated brain 2-arachidonoylglycerol negatively modulates the CRF-induced activation of central sympatho-adrenomedullary outflow in rats.
In the next experiment, we examined the effect of exogenously administered ACEA, a selective agonist of cannabinoid CB 1 receptors (Hillard et al., 1999) , on the centrally administered CRF-induced elevation of plasma catecholamines. This agonist administered into the dorsolateral periaqueductal gray induces an anxiolytic effect in rats and centrally administered this reagent decreases the frequency of epileptiform activity in epilepsy model rats (Moreira et al., 2007; Kozan et al., 2009) . In the present experiment, centrally administered ACEA effectively reduced the CRF-induced elevation of plasma catecholamines, but peripherally administered ACEA had no effect.
The result indicates that exogenously administered cannabinoid CB 1 receptor agonist 18 into the brain further inhibits the CRF-induced activation of central sympathoadrenomedullary outflow in addition to the inhibition induced by CRF-induced endogenously generated brain 2-arachidonoylglycerol.
Centrally administered cannabinoid CB 1 receptor agonists can inhibit the activation of central sympatho-adrenomedullary outflow. However, one of the major drawbacks of the use of agonists is that cannabinoid CB 1 receptors have a widespread distribution in the brain (Howlett et al., 2002; Mackie, 2008) and global activation of these receptors is associated with adverse side effects such as sedation, dependence, cognitive impairment and psychosis (Kalant, 2004; Pacher et al., 2006) . On the other hand, endocannabinoid uptake-inhibitors can elevate the synaptic content of endocannabinoid at sites of high endocannabinoid turnover. From our studies, brain 2-arachidonoylglycerol can be endogenously generated during the CRF-induced activation of central sympatho-adrenomedullary outflow and the activation was effectively inhibited by centrally administered AM 404 (an uptake-inhibitor of endocannabinoid). Furthermore, Brozoski et al. reported that AM 404 administered in the nucleus tractus solitarius after an increase in blood pressure prolongs baroreflex inhibition of renal sympathetic nerve activity in rats (Brozoski et al., 2005) . These lines of evidence suggest a possibility that endocannabinoid uptake-inhibitors can locally activate cannabinoid CB 1 receptors at sites of high endocannabinoid turnover and inhibit the activation of central sympatho-adrenomedullary outflow. Taken together, it is suggested that endocannabinoid uptake-inhibitors rather than agonists of cannabinoid CB 1 receptors are beneficial targets for therapeutic drugs to inhibit central sympatho-adrenomedullary outflow without adverse side effects on other brain functions.
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In summary, it seems likely that brain 2-arachidonoylglycerol is endogenously generated during the centrally administered CRF-induced activation of sympathoadrenomedullary outflow, thereby inhibiting the peptide-induced response by brain cannabinoid CB 1 receptor-mediated mechanisms in anesthetized rats. 
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